title: PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.
abstract: Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET/CT) using18F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology. This paper reviews the recent advances as well as the potential place of a more specific radiopharmaceutical in MM.
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. clement.bailly@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. clement.bailly@chu-nantes.fr.
authors.forename: Clément
authors.initials: C
authors.lastname: Bailly
authors.affiliation: Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. rodolpheleforestier@hotmail.fr.
authors.forename: Rodolphe
authors.initials: R
authors.lastname: Leforestier
authors.affiliation: Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. bastien.jamet@chu-nantes.fr.
authors.forename: Bastien
authors.initials: B
authors.lastname: Jamet
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. thomas.carlier@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. thomas.carlier@chu-nantes.fr.
authors.forename: Thomas
authors.initials: T
authors.lastname: Carlier
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. mickael.bourgeois@nantes.inserm.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. mickael.bourgeois@nantes.inserm.fr.
authors.forename: Mickael
authors.initials: M
authors.lastname: Bourgeois
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. francois.guerard@univ-nantes.fr.
authors.forename: François
authors.initials: F
authors.lastname: Guérard
authors.affiliation: Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. cyrille.touzeau@chu-nantes.fr.
authors.forename: Cyrille
authors.initials: C
authors.lastname: Touzeau
authors.affiliation: Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. philippe.moreau@chu-nantes.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. michel.cherel@univ-nantes.fr.|Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France. michel.cherel@univ-nantes.fr.
authors.forename: Michel
authors.initials: M
authors.lastname: Chérel
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. francoise.bodere@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. francoise.bodere@chu-nantes.fr.|Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France. francoise.bodere@chu-nantes.fr.
authors.forename: Françoise
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.affiliation: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. caroline.milin@chu-nantes.fr.|Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. caroline.milin@chu-nantes.fr.
authors.forename: Caroline
authors.initials: C
authors.lastname: Bodet-Milin
mesh_terms: D001847:Bone Diseases / Q000175:diagnosis / Q000209:etiology; D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000175:diagnosis; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: PET/CT; multiple myeloma; solitary plasmacytoma; therapeutic evaluation